Is Pentraxin-3 a Stronger Marker of Inflammation than C-Reactive Protein in Chronic Kidney Disease? by unknown
Turk Neph Dial Transpl 2014; 23 (2): 131-136
131
Özgün Araştırma/Original Investigation
Is Pentraxin-3 a Stronger Marker of Inflammation than C-Reactive 
Protein in Chronic Kidney Disease?
Pentraksin-3 Kronik Böbrek Hastalığında C-Reaktif Proteinden Daha 
Güçlü Bir Enflamasyon Belirteci midir?
Meltem Gürsu1
Zeki AydIn1
Savaş Öztürk1
Serhat KArAdAğ1
Sami UZUn1
yasemin dÖventAş erdOğAn2
Macit KOldAş2
Abdullah şUMnU1
egemen CebeCi1
Oktay ÖZKAn1
rümeyza KAZAnCIOğlU3
1  Haseki Training and Research Hospital, 
Department of Nephrology, 
  İstanbul, Turkey
2  Haseki Training and Research Hospital, 
Department of Clinical Biochemistry, 
İstanbul, Turkey
3  Bezmialem Vakif University, Faculty of 
Medicine, Department of Nephrology, 
İstanbul, Turkey
doi: 10.5262/tndt.2014.1002.09
Correspondence Address:
Savaş Öztürk
Haseki Eğitim ve Araştırma Hastanesi, 
Nefroloji Bölümü, İstanbul, Turkey
Phone  : + 90 212 529 44 00
E-mail  : savasozturkdr@yahoo.com
Received : 19.12.2013
Accepted : 21.01.2014
AbstrAct
ObJeCtIve: Pentraxin-3 (PTX-3) is elevated in uremic patients and related with albuminuria and 
endothelial dysfunction. We aimed to clarify the relationship of PTX-3 with inflammatory markers 
(hsCRP and IL-6) in patients with chronic kidney disease (CKD). 
MAterIAl and MetHOdS: The study was performed with four groups: hemodialysis (HD) group 
(23 patients), peritoneal dialysis (PD) group (25 patients), predialysis group (stage-4 CKD, 25 patients) 
and the healthy control group (18 individuals). GFR was estimated by the MDRD formula. PTX-3, IL-
6, fibrinogen, hsCRP levels, glucose, urea, creatinine, uric acid, parathyroid hormone, albumin, LDL 
cholesterol, HDL cholesterol, triglyceride, ferritin, and hemoglobin were studied from the serum and 
whole blood samples.
reSUltS: PTX-3 levels were highest in the HD group followed by the PD group, pre-dialysis group 
and control group (3.58±4.29, 2.15±2.75, 1.29±2.36, 0.73±0.96 ng/ml, respectively). IL-6 levels were 
highest in the PD group followed by the HD, predialysis and control groups. There was no difference 
between groups regarding hsCRP levels. There was no correlation of PTX-3 with hsCRP, while it was 
correlated with IL-6. IL-6 was the only determinant of PTX-3 level independent of the study groups 
and vice versa.
COnClUSIOn: Uremic patients have elevated PTX-3 levels and it is strongly correlated with IL-6. 
PTX-3 may be superior to CRP as an inflammation marker in the uremic population.
Key wOrdS: C-reactive protein, Inflammation, Interleukin-6, Pentraxin-3, Uremia
Öz
AMAÇ: Pentraksin-3 (PTX-3) düzeyleri üremik hastalarda yüksektir ve hem albüminüri ile hem de 
endotelyal disfonksiyonla ilişkilidir. Bu çalışmada, kronik böbrek hastalığı (KBH) olan hastalarda 
PTX-3’ün enflamatuvar belirteçler (hsCRP ve IL-6) ile arasındaki ilişkiyi araştırmayı amaçladık. 
GereÇ ve yÖnteMler: Çalışma 4 grupta yapıldı: hemodiyaliz (HD) grubu (23 hasta), periton 
diyalizi (PD) grubu (25 hasta), prediyaliz grubu (evre-4 KBH, 25 hasta) ve sağlıklı kontrol grubu 
(18 kişi). Glomerüler filtrasyon hızı (GFH), MDRD formülüne göre hesaplandı. Serum ve tam kan 
örneklerinden; PTX-3, IL-6, fibrinojen, hsCRP düzeyleri, glukoz, üre, kreatinin, ürik asit, paratiroid 
hormonu, albümin, LDL kolesterol, HDL kolesterol, trigliserid, ferritin, hemoglobin düzeyleri çalışıldı.
bUlGUlAr: PTX-3 düzeyi HD grubunda en yüksek idi, onu PD, prediyaliz ve kontrol grupları izledi 
(sırasıyla 3,58±4,29, 2,15±2,75, 1,29±2,36, 0,73±0,96 ng/ml). IL-6 seviyeleri PD grubunda en yüksek 
idi, ardından HD grubu, prediyaliz ve kontrol grupları izledi. hsCRP düzeylerinde gruplar arasında 
anlamlı bir fark yoktu. PTX-3 ile IL-6 arasında anlamlı korelasyon izlenirken, PTX-3 ile hsCRP 
arasında ilişki saptanmadı. IL-6 çok değişkenli analizde PTX-3’ün tek bağımsız belirleyicisi olarak 
bulunurken, IL-6’nın tek bağımsız belirleyicisi de PTX-3 idi. 
SOnUÇ: Üremik hastalarda PTX-3 düzeyleri yükselmiştir ve IL-6 ile kuvvetli ilişki göstermektedir. 
PTX-3, üremik popülasyonda bir enflamasyon belirteci olarak hsCRP’den üstün olabilir.
AnAHtAr SÖZCüKler: CRP, Enflamasyon, İnterlökin-6, Pentraksin-3, Üremi132
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IntrOdUCtIOn
Chronic kidney disease (CKD) is associated with increased 
cardiovascular morbidity and mortality even in the early stages of 
the disease (1). It has been shown that innate and acquired immune 
system has a role in atherogenesis and hence in cardiovascular 
risk (2, 3). The pro-inflammatory/anti-inflammatory phenotype 
is disturbed on the pro-inflammatory side in CKD patients (4). 
The immune cells located at the atherosclerotic sites produce 
many cytokines such as interleukins (IL), tumor necrosis factor, 
interferon-α and platelet derived growth factor (5). Fibrinogen, 
IL-6,  IL-18,  myeloperoxidase,  C-reactive  protein  (CRP)  and 
hyaluronan levels have been reported to be elevated in uremic 
patients  (6-10).  IL-6  has  pro-inflammatory  effects,  promotes 
the production of proteins that have roles in the early stages on 
inflammation, and activates peripheral mononuclear cells and 
differentiation of B cells. 
Recent  studies  propose  IL–6  as  a  more  valuable  marker 
than CRP in the determination of the degree of inflammation 
and  cardiovascular risk  (11).  On  the  other  hand,  there  is  no 
consensus about their role in the diagnosis of these diseases 
because one reason for elevated serum levels is the decreased 
renal  elimination  in  uremic  patients. There  are  contradicting 
reports about the correlation between the clinical-radiological 
findings  and  inflammatory  markers  in  CKD  patients  (12). 
Additionally, CRP and homocystein have been claimed recently 
to be anti-atherogenic (13-15).
Pentraxins  are  a  family  of  pattern  recognition  proteins; 
and are divided into two groups. CRP and amyloid-p protein 
account  for  the  short  pentraxins  and  pentraxin-3  (PTX-3)  is 
the  prototype  of  the  long  pentraxins.  PTX-3  is  produced  by 
vascular endothelial cells, smooth muscle cells, macrophages 
and adipose tissue in response to pro-inflammatory signals and 
stimulation of Toll-like receptors (16). PTX-3 expression has 
been shown in renal proximal tubular cells, renal fibroblasts 
and  mesangial  cells  (17).  It  has  a  molecular  weight  of  40.6 
kDa, and is present in the circulation in the form of multimers. 
It facilitates opsonization; it activates the complement system 
and leads to killing of opsonized cells and microbes (18). It is 
regarded as an independent marker of disease activity due to its 
synthesis directly at the site of inflammation. Uremic patients 
have  high  PTX-3  levels,  which  are  related  with  increased 
mortality independent of CRP (6, 19); it has a more stable course 
than CRP (20). The relationship of PTX-3 with CRP has been 
reported to be weak in some studies (13, 21). Suliman et al found 
that  PTX-3,  albuminuria  and  endothelial  dysfunction  are  all 
interrelated (22). Herein we aimed to clarify the relationship of 
PTX-3 with CRP and IL-6 in patients in various stages of CKD.
MAterIAl and MetHOdS
The study was a cross-sectional study involving four groups: 
the hemodialysis (HD) group consisted of HD patients between 
the ages of 18 and 80 years with a duration of HD of at least three 
months and Kt/V and urea reduction ratio above the target level 
described by international guidelines. The peritoneal dialysis 
(PD) group consisted of PD patients between the age of 18 and 
80 years with duration of PD of at least three months and Kt/V 
values over target levels as described by international guidelines. 
The  modality  of  PD  was  not  a  criterion  for  inclusion.  The 
predialysis (stage 4 CKD) group consisted of patients between 
the age of 18 and 80 years with a stable estimated glomerular 
filtration rate (eGFR) less than 30 ml/min. The control group 
consisted of nonuremic volunteers between the age of 18 and 80 
years without any infectious or inflammatory disease within the 
last three months.
The study was initiated after the approval of the local ethics 
committee of our hospital on 13.04.2009. An informed consent 
form was signed by all the participants. Patients with diabetic 
nephropathy,  acute  infectious/inflammatory  disease,  acute 
ischemic vascular disease, chronic inflammation, chronic liver 
disease and those with venous catheters as vascular access were 
excluded from the study. 
Demographic  parameters  (age,  gender,  body  mass  index- 
BMI-), systolic and diastolic blood pressures, primary kidney 
disease  and  comorbidities  (hypertension,  morphologically 
proven coronary artery disease, peripheral artery disease) and 
the duration of dialysis were recorded. GFR was estimated by 
the MDRD formula. Blood samples were obtained from HD 
patients  before  the  midweek  session;  and  from  PD  patients 
after  12  hours  of  fasting  with  their  abdomen  left  empty  the 
night before. PTX-3, IL-6, fibrinogen, hsCRP as well as blood 
glucose, urea, creatinine, uric acid, parathyroid hormone (PTH), 
albumin,  LDL  cholesterol,  HDL  cholesterol,  triglyceride, 
ferritin, and hemoglobin (Hb) levels were measured from the 
serum and whole blood samples. PTX-3 and IL-6 levels were 
measured by the ELISA (enzyme linked immunosorbent assay) 
technique.
Statistical  analysis  was  performed  using  SPSS  (for 
Windows  15.0,  standard  version)  software.  Quantitative  data 
were  presented  as  mean  value±standard  deviation  (SD). The 
Student  t-test  and  Mann-Whitney  U  test  were  used  in  the 
comparison of two groups, as appropriate. One-way analysis 
of variance (ANOVA) or Kruskal Wallis-H variance analysis 
was appropriately used in the comparison of more than two 
groups. Bonferroni correction was applied to alpha significance 
level. Pearson or Spearman’s (rho) correlation test was used 
in  the  correlation  analysis  between  quantitative  parameters. 
P<0.05 was accepted as significant. The parameters found to 
be related with PTX-3 in univariate analyses were examined by 
multivariate analysis using the “stepwise” method. 
reSUltS
Ninety one individuals were included in the study (23, 25 and 
25 patients in the HD, PD and predialysis groups respectively; and 
18 nonuremic subjects as the control group). The demographic 133
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and clinical data of the patients are presented in Table I. The 
mean ages in the predialysis and control groups were higher than 
in the PD group (p=0.025 and p=0.023, respectively). Groups 
were similar regarding gender. 
Patients in the predialysis, PD and control groups had higher 
BMI values than the HD group (p=0.003, p=0.011 and p<0.001 
respectively). The duration of dialysis was longer in the HD group 
(56.71±41.97 months vs. 32.12±19.67 months, p=0.046). There 
was no difference between the groups regarding primary kidney 
disease (p=0.553). There were two patients in the HD group with 
radiologically proven coronary artery disease (p=0.09); while no 
patient had documented peripheral vascular disease (p=0.325).
The  biochemical  and  hematological  parameters  and  the 
comparisons between each group are presented in Table II. 
Table II: Biochemical and hematological parameters (mean ± standard deviation). 
HD group PD group Predialysis group Control group p
Glucose (mg/dl) 101±25 99±23 112±40 100±9 NS
Urea (mg/dl) 108±34 99±19 108±37 31±10 <0.001a,b,c
Creatinine (mg/dl) 7.3±1.9 7.9±2.6 3.5±1.5 0.8±0.1 <0.001a,b,c, d, e
Uric acid (mg/dl) 5.3±1.6 5.8±1.4 7.6±1.5 5.0±1.3 <0.001a,d,e; 0.047c
eGFR (ml/min) - 4.1±4.2 21.7±7.5 104±16 <0.001a,c,e
Albumin (g/dl) 4.1±0.4 3.6±0.3 3.8±0.8 4.2±0.3 0.037a; <0.001c
PTH (pg/ml) 581±523 548±445 286±156 67±44 <0.001a,b,c,d, 0.013e
LDL cholesterol (mg/dl) 107±35 112±35 130±56 137±30 0.007b; <0.001c
HDL cholesterol(mg/dl) 38±11 44±15 43±10 49±13 0.006b; <0.001c
Triglyceride (mg/dl) 214±134 202±223 149±71 114±57 0.001b; 0.03c ; 0.027d
Hb (g/dl) 11.8±1.2 10.5±1.7 11.3±2.0 13.5±1.1 <0.001a,b,c ; 0.004f
Ferritin (ng/ml) 764±415 431±912 186±173 81±55 <0.001b,c,d,f; 0.028e
NS: Not significant, a: Predialysis-control, b: HD-control, c: PD-control, d: Predialysis-HD, e: Predialysis-PD, f: HD-PD.
Table I: Demographic and clinical parameters.
HD group (n=23) PD group (n=25) Predialysis group (n=25) Control group (n=18)
Age (years) 48.2±11.9 45.7±12.5 55.3±16.2 54.9±8.3
Female/male ratio 9/14 16/9 14/11 10/8
BMI (kg/m2) 23.16±3.65 28.13±7.18 26.47±3,67 27.96±4.5
Systolic BP(mmHg) 119±10 136±28 133±14 115±10
Diastolic BP(mmHg) 73±7 81±13 81.60±12 71±8
P
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Unknown 8 8 8 -
Nephrosclerosis 6 4 5 -
Chronic glomerulonephritis 4 5 5 -
Chronic Pyelonephritis 3 2 3 -
ADPCKD 1 5 1 -
Amyloidosis 1 1 3 -
BMI: Body mass index; BP: Blood pressure; ADPCKD: Autosomal dominant polycystic kidney disease.134
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Levels of inflammatory markers are presented in Table III. 
PTX-3 levels were highest in the HD group followed by the PD, 
predialysis and the control groups. PTX-3 levels in the HD and 
PD groups were statistically significantly higher than the control 
group. Predialysis patients had significantly lower PTX-3 levels 
compared with the HD group. IL-6 levels were highest in the 
PD group followed by the HD and predialysis groups. Patients 
in the HD and PD groups had significantly higher IL-6 levels 
than those in the control group. There was no difference between 
the hsCRP levels of the patient groups. Fibrinogen levels were 
similar in predialysis and control groups but was lower than the 
values reported in HD and PD groups. 
The  analysis  was  repeated  after  dividing  the  subjects 
into three groups as the dialysis group (PD and HD groups), 
predialysis group and control group (Table IV). Uremic patients 
(dialysis  and  predialysis)  had  higher  levels  of  PTX-3,  IL-6, 
hsCRP and fibrinogen levels than the control group. All these 
inflammatory markers were significantly different between the 
dialysis group and control group. Additionally, the predialysis 
group had higher fibrinogen levels than the control group; and 
the  dialysis  group  had  a  higher  mean  hsCRP  level  than  the 
predialysis group. 
In univariate analysis; PTX-3 was found to be positively 
correlated  with  serum  creatinine  (r=0.241,  p=0.024),  PTH 
(r=0.232,  p=0.038)  and  IL-6  (r=0.784,  p<0.001)  (Figure  1); 
while  it  was  negatively  correlated  with  eGFR  (r=-0.247, 
p=0.02). There  was  no  correlation  of  PTX-3  with  CRP  (r=-
0.018, p=0.873) and fibrinogen (r=0.239, p=0.052). IL-6 was 
correlated positively with fibrinogen (r=0.270, p=0.027); and 
negatively with albumin (r=-0.295, p=0.015). When correlation 
analysis was repeated excluding the control group, significant 
correlations  were  found  between  IL-6  and  PTX-3  (r=0.790; 
p<0.001). There was no relation of PTX-3 and IL-6 levels with 
CRP levels.
Table III: Levels of inflammatory markers. 
HD group PD group Predialysis group Control group p
IL-6 (pg/ml) 40±64 47±102 24±49 16±28 0.046b; 0.008c
PTX-3 (ng/ml) 3.58±4.29 2.15±2.75 1.29±2.36 0.73±0.96 <0.001b; 0.034c; 0.006d
hsCRP (mg/l) 0.97±0.79 1.02±1.29 1.06±0.82 0.47±0.59 0.024a
Fibrinogen (mg/dl) 436±112 568±110 401±89 347±104 <0.001c,e; 0.001f; 0.012b
NS: Not significant, a: Predialysis-control, b: HD-control, c: PD-control, d: Predialysis-HD, e: Predialysis-PD, f: HD-PD,
Table IV: Levels of inflammatory markers when HD and PD patients are considered as the dialysis group.
Dialysis group Predialysis group Control group p
IL-6 (pg/ml) 42.2±85.6 24.0±49.2 16.0±28.3 0,019a
PTX-3 (ng/ml) 2.81±3.57 1.29±2.36 0.73±0.96 0,001a
hsCRP (mg/l) 0.99±1.07 1.06±0.82 0.47±0.59 0.016a, 0,005c
Fibrinogen (mg/dl) 505±128 401±89 347±104 0.001a, 0,015b
NS: Not significant, a: Dialysis-control, b: Predialysis-dialysis, c: Predialysis-control.
Figure 1: The figure showing correlation between IL-6 and PTX-3135
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cardiovascular risk (11). Hence these data combined with our 
findings may lead to the idea that PTX-3 is superior to CRP as a 
marker of inflammation in patients with uremia.
The difference in PTX-3 levels between PD and HD groups, 
although statistically nonsignificant, may also be caused by the 
difference in the clearance of PTX-3, which has a molecular 
weight of 40.6 kDa. Better residual renal function and higher 
clearance of high molecular weight substances in PD may cause 
higher PTX-3 clearance although there is no clear knowledge 
about the route of clearance (27). The strong correlation between 
IL-6 and PTX-3 may be a finding supporting the use of PTX-3 as 
a reliable marker of inflammation. 
CRP, known as a marker of inflammation and cardiovascular 
risk, was found to be correlated with PTX-3 in some studies 
while  not  in  others  (21).  The  relationship  of  PTX-3  with 
mortality was shown in a study in which no correlation with 
CRP levels was detected in patients in the intensive care unit 
(21). However, prospective studies are warranted to show the 
power of PTX-3 as a cardiovascular prognostic factor.
The major defect of the present study is the cross-sectional 
nature with non-homogeneous groups. However, we included 
age, gender and study group in multivariate analyses to eliminate 
the probable effect of these parameters. 
COnClUSIOn
PTX-3 is superior to CRP as an inflammation marker and 
strongly correlates with IL-6 in the uremic population. This may 
be a finding supporting the use of PTX-3 as a reliable marker of 
inflammation. 
reFerenCeS
1.  Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lamiere 
N: Chronic kidney disease as a cause of cardiovascular morbidity 
and mortality. Nephrol Dial Transpl 2005; 20: 1048-1056
2.  Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 
1999; 340: 115-126
3.  Hansson  GK:  Inflammation,  atherosclerosis  and  coronary  artery 
disease. N Engl J Med 2005; 352: 1685-1695
4.  Methe H, Edelman ER: Cell-matrix contact prevents recognition 
and damage of endothelial cells in states of heightened immunity. 
Circulation 2006; 114 (Suppl 1): 1233-1238
5.  Kofler S, Nickel T, Weis M: Role of cytokines in cardiovascular 
diseases: A focus on endothelial responses to inflammation. Clin Sci 
2005; 108: 205-213
6.  Tong  M,  Carrero  JJ,  Qureshi  AR,  Anderstam  B,  Heimbürger 
O, Bárány P, Axelsson J, Alvestrand A, Stenvinkel P, Lindholm 
B,  Suliman  ME:  Plasma  pentraxin-3  in  chronic  kidney  disease 
patients: Associations with renal function, protein-energy wasting, 
cardiovascular disease and mortality. Clin J Am Soc Nephrol 2007; 
2: 889-897
Multivariate analysis was conducted using the parameters 
with  p  values  less  than  0.1  in  univariate  analysis  with  the 
addition  of  age,  gender,  study  group,  blood  pressures  and 
creatinine  values.  IL-6  was  the  only  determinant  of  PTX-3 
level independent of the study groups and vice versa (p<0.001). 
Fibrinogen and hsCRP levels did not have a significant effect 
on PTX-3 levels. The factors affecting hsCRP were creatinine 
(p=0.004) and fibrinogen (p<0.001) levels and the study group 
(p=0.049). 
dISCUSSIOn
CKD has been shown to be associated with chronic low-
grade  inflammation  together  with  increased  cardiovascular 
risk  in  many  studies.  Many  biochemical  markers  detected 
those at risk but were not accepted as a surrogate marker for 
diagnosis and follow-up. IL-6 plays a central role in the onset of 
inflammation. We aimed to evaluate the inflammatory status of 
patients in different stages of CKD and to study the correlation 
of PTX-3 with other inflammatory markers, especially CRP. We 
found out that there was a strong relationship between IL-6 and 
PTX-3. Furthermore, PTX-3 was the only parameter that showed 
a relationship with IL-6 in multivariate analyses regardless of 
renal function status. There was no correlation between IL-6 and 
CRP level in univariate analyses. 
PTX-3 is one of the markers found to be elevated in CKD 
with levels increasing with the degree of renal impairment and 
the duration of dialysis (6). It was reported to be related with 
endothelial dysfunction, malnutrition, proteinuria and increased 
mortality rate (22, 24, 25). In our study, the PTX-3 level also 
increased with an increasing degree of renal impairment. The 
lower levels in the PD group compared with the HD group, 
although statistically not significant, may be explained by the 
absence of the potential reactions to dialysis membranes, lack 
of  potential  infections  of  vascular  access  and  residual  renal 
function that is sustained for longer periods in PD treatment. 
The higher residual renal function detected in the PD patients 
of the study group is consistent with this fact. Otherwise, longer 
duration of dialysis may be another possible explanation for 
higher PTX-3 levels. The higher mean age in the HD group may 
also be suspected as a cause but the linear regression analysis 
revealed  no  association  between  age  and  PTX-3  levels. The 
primary  explanation  should  be  the  difference  in  IL-6  levels. 
Subclinical infections not determined by usual methods may be 
another factor influencing the levels. 
There are some studies supporting our results. Tong et al (6) 
found that the relation between IL-6 and PTX-3 was stronger 
than that between IL-6 and CRP. It has been shown by previous 
studies that PTX-3 has a more stable course (20). It was shown 
to be weakly correlated with CRP (13, 21), while more closely 
related with IL-6 (6). IL-6 has been found to be correlated with 
PTX-3 strongly and to also stimulate its synthesis (26). IL-6 
has been reported to be more strongly associated with increased 136
türk nefroloji diyaliz ve transplantasyon dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
Gürsu M et al : Is Pentraxin-3 a Stronger Marker of Inflammation than                     
C-Reactive Protein in Chronic Kidney Disease?
Turk Neph Dial Transpl 2014; 23 (2): 131-136
7.  Pecoitz-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel 
P:  Interleukin-6  and  its  receptor  is  an  independent  predictor  of 
mortality  in  patients  starting  dialysis  treatment.  Nephrol  Dial 
Transpl 2002; 17: 1684-1688
8.  Chiang CK, Hsu HP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, 
Tsai TJ:  Interlekin-18  is  a  strong  predictor  of  hospitalization  in 
hemodialysis patients. Nephrol Dial Transpl 2004; 19: 2810-2815
9.  Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino 
LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli 
B,  Nicocia  G,  Buemi  M:  Fibrinogen,  mortality  and  incident 
cardiovascular  complications  in  end-stage  renal  failure.  J  Intern 
Med 2003; 254: 132-139
10. Zimmermann  J,  Herrlinger  S,  Pruy  A,  Metzger  T,  Wanner  C: 
Inflammation  enhances  cardiovascular  risk  and  mortality  in 
hemodialysis patients. Kidney Int 1999; 55: 648-658
11. Filiopoulos V, Vlassopoulos D: Inflammatory syndrome in chronic 
kidney disease: Pathogenesis and influence on outcomes. Inflamm 
Allergy Drug Targets 2009; 8: 369-382
12. Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic 
N, Westenfeld R, Dimkovic N, Ketteler M, Floege J: Is there a 
correlation between C-reactive protein and calcification inhibitors 
with  cardiovascular  parameters  and  risk  factors  in  hemodialysis 
patients? Dtsch Med Wochenschr 2007; 132: 1820-1824
13. Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, Björkegren: 
Human C-reactive protein slows atherosclerosis development in a 
mouse model with human-like hypercholesterolemia. J Proc Natl 
Acad Sci USA 2007; 104: 13768-13773
14. Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Bárány P, 
Heimbürger O, Vonesh EF, Lindholm B: The reverse epidemiology 
of plasma total homocystein as a mortality risk factor is related 
to the impact of wasting and inflammation. Nephrol Dial Transpl 
2007; 22: 209-217
15. Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel 
P:  Homocystein  in  uraemia:  A  puzzling  and  conflicting  story. 
Nephrol Dial Transpl 2005; 20: 16-21
16. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de 
la Torre Y, Latini R: The long pentraxin PTX3 in vascular pathology. 
Vascul Pharmacol 2006; 45: 326-330
17. Nauta AJ, de Haij S, Bottazzi B, Mantovani A, Borrias MC, Aten 
J, Rastaldi MP, Daha MR, van Kooten C, Roos A: Human renal 
epithelial cells produce the long pentraxin PTX3. Kidney Int 2005; 
67: 543-553
18. Boehme  M,  Kaehne  F,  Kuehne  A,  Bernhardt  W,  Schröder  M, 
Pommer W, Fischer C, Becker H, Müller C, Schindler R: Pentraxin 
3  is  elevated  in  hemodialysis  patients  and  is  associated  with 
cardiovascular disease. Nephrol Dial Int 2007; 22: 2224-2229
19. Suliman  ME,  Qureshi  AR,  Carrero  JJ,  Bárány  P,  Yilmaz  MI, 
Snaedal-Jonsdottir S, Alvestrand A, Heimbürger O, Lindholm B, 
Stenvinkel P: The long pentraxin PTX-3 in prevalent hemodialysis 
patients:  Associations  with  co-morbidities  and  mortality.  QJM 
2008; 101: 397-405
20. Malaponte G, Libra M, Bevelacqua Y, Merito P, Fatuzzo P, Rapisarda 
F, Cristina M, Naselli G, Stivala F, Mazzarino MC, Castellino P: 
Inflammatory status in patients with chronic renal failure: The role 
of PRX3 and pro-inflammatory cytokines. Int J Mol Med 2007; 20: 
471-481
21. Muller B, Peri G, Torri V, Landmann R, Bottazzi B, Mantovani 
A: Circulating levels of long pentraxin PTX3 correlate with the 
severity of infection in critically ill patients. Crit Care Med 2001; 
29: 1404-1407
22. Suliman  ME,  Yilmaz  MI,  Carrero  JJ,  Qureshi  AR,  Saglam  M, 
Ipcioglu  OM,  Yenicesu  M,  Tong  M,  Heimbürger  O,  Barany  P, 
Alvestrand A, Lindholm B, Stenvinkel P: Novel links between the 
long pentraxin-3, endothelial dysfunction, and albuminuria in early 
and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008; 
3: 976-985
23. Kalantar-Zadeh K: Inflammatory marker mania in chronic kidney 
disease:  Pentraxins  at  the  crossroad  of  universal  soldiers  of 
inflammation. Clin J Am Soc Nephrol 2007; 2: 872-875
24. Şahin  E,  Bulucu  F,  Karaman  M,  Ay  AS,  Sağlam  M,  Çakir  E, 
Yilmaz  Mİ:  The  Relationship  between  endothelial  dysfunction 
and pentraxin-3 concentration in chronic kidney disease. Turkish 
Nephrology, Dialysis and Transplantation Journal 2010; 19: 192-
198
25. Pawlak K, Pawlak D, Mysliwiec M: Impaired renal function and 
duration  of  dialysis  therapy  are  associated  with  oxidative  stress 
and proatherogenic cytokine levels in patients with end-stage renal 
disease. Clin Biochem 2007; 40: 81-85
26. Diefenbach  CW,  Tramont  EC,  Plaeger  SF:  Section  B:  Host 
Defense Mechanisms. Innate (general or nonspecific) host defense 
mechanisms. In: Mandell GL, Bennett JE, Dolin R (eds), Mandell, 
Douglas and Bennet’s Principles and Practice of Infectious Diseases. 
(Fifth ed). Newyork: Chuchill Livingstone, 2009
27. Lysaght MJ, Pollock CA, Moran JE, Ibels LS, Farrell PC: Beta-
2 microglobulin removal during continuous ambulatory peritoneal 
dialysis (CAPD). Perit Dial Int 1989; 9: 29-35